People: Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

4.05USD
16 Apr 2014
Price Change (% chg)

$0.36 (+9.76%)
Prev Close
$3.69
Open
$3.74
Day's High
$4.06
Day's Low
$3.74
Volume
3,657,797
Avg. Vol
4,896,163
52-wk High
$6.95
52-wk Low
$1.68

Search Stocks

Summary

Name Age Since Current Position

James Young

60 2011 Independent Chairman of the Board

Stanley Erck

64 2011 President, Chief Executive Officer, Director

Barclay Phillips

49 2013 Chief Financial Officer, Senior Vice President

Gregory Glenn

59 2014 Senior Vice President - Research & Development

Timothy Hahn

49 2011 Senior Vice President - Manufacturing and Process Development

Cynthia Oliver

2014 Senior Vice President - Process Development Operations

John Trizzino

51 2014 Senior Vice President - Commercial Operations

Russell Wilson

53 2011 Senior Vice President - Business Development

Louis Fries

2014 Vice President, Chief Medical Officer

D. Nigel Thomas

2014 Vice President - Clinical Operations

Rajiv Modi

53 2009 Director

Richard Douglas

60 2010 Independent Director

Gary Evans

56 2011 Independent Director

John Marsh

86 1997 Independent Director

Michael McManus

70 1998 Independent Director

Biographies

Name Description

James Young

Dr. James F. Young is an Independent Chairman of the Board of Novavax, Inc. since April 2011. He was Former President, Research and Development, MedImmune, Inc. Dr. Young has been Chairman of the Board since April 2011 and a Director of Novavax since April 2010. He has over 30 years of experience in the fields of molecular genetics, microbiology, immunology, and pharmaceutical development. From December 2000 until June 2008, Dr. Young held the position of President, Research and Development, at MedImmune. Dr. Young joined MedImmune in 1989 as Vice President, Research and Development. In 1995, he was promoted to Senior Vice President and in 1999 he was promoted to Executive Vice President, Research and Development. Dr. Young brings extensive scientific background and experiences, particularly in the areas of vaccine research and development.

Stanley Erck

Mr. Stanley C. Erck is President, Chief Executive Officer, Director of Novavax, Inc., since April 19,2011. He is Former Executive Chairman and Director of Novavax from February 2010 until April 2011, and a Director since June 2009. From 2000 to 2008, Mr. Erck served as President, Chief Executive Officer and Director of Iomai Corporation, a vaccine development company, which was acquired in 2008 by Intercell. He previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now known as Genzyme, and Baxter International. Mr. Erck currently serves on the boards of BioCryst Pharmaceuticals, MaxCyte, Inc. and the MdBio Foundation. Mr. Erck is a serial entrepreneur in the biotechnology industry, having grown and provided successful exit strategies, including two IPOs and an acquisition, for several companies, and has many years of experience serving on other companies’ boards.

Barclay Phillips

Mr. Barclay A. Phillips is Chief Financial Officer, Senior Vice President of Novavax, Inc. Prior to joining Novavax, Mr. Phillips was Senior Vice President and Chief Financial Officer of Micromet, Inc. which was acquired by Amgen in 2012. Previously, he was Managing Director of Vector Fund Management and a Biotechnology Analyst and Director of Venture Investments at Invesco Funds Group, Inc.

Gregory Glenn

Dr. Gregory M. Glenn M.D. is Senior Vice President of Research and Development of Novavax, Inc. He served as Senior Vice President and Chief Scientific Officer from July 2010 to January 2011. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired in 2008 by Intercell AG, an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research.

Timothy Hahn

Dr. Timothy J. Hahn Ph.D. is Senior Vice President - Manufacturing and Process Development of Novavax Inc., since June 28, 2011.Prior to joining the Company, Dr. Hahn was Vice President of Antibody Manufacturing and later Vice President of Vaccine Manufacturing at MedImmune, LLC, with responsibilities for both U.S. and non-U.S. manufacturing sites. Dr. Hahn spent more than 15 years in vaccine manufacturing with Merck & Co.

Cynthia Oliver

Dr. Cynthia N. Oliver, Ph.D. is Senior Vice President - Process Development Operations of the Company. Dr. Oliver has been a consultant of Novavax since 2011 where her significant expertise and experiences have helped the Company formulate and execute on critical process development strategies. From 1993 until 2010, Dr. Oliver held a variety of positions, including Vice President, Process Biochemistry and Formulation Sciences at Medimmune, Inc., with responsibilities that included vaccines, proteins, monoclonal antibodies and small molecules, including the commercial products Synagis® and FluMist®. Prior to MedImmune, she had similar responsibilities at Merck Research Laboratories, and spent a number of years working at the National Institutes of Health in the National Heart, Lung and Blood Institute. She earned her doctorate from Johns Hopkins, her masters from University of Massachusetts, and her bachelor’s degree from Connecticut College.

John Trizzino

Mr. John J. Trizzino is Senior Vice President - Commercial Operations of Novavax, Inc. Mr. Trizzino previously served as Novavax' Senior Vice President of International and Government Alliances beginning in 2009 and its Senior Vice President of Business Development from 2010 to 2011. In these roles, Mr. Trizzino played a key role in negotiating the company's $179 million contract with HHS BARDA. Mr. Trizzino brings the depth and breadth of vaccine industry knowledge, along with extensive experience with the global influenza and RSV markets, required for this position. Most recently he was the CEO of Immunovaccine, and prior to his time at Novavax, served as Vice President of the Vaccine Franchise at MedImmune LLC, Senior Vice President of Business Development at ID Biomedical and Vice President of Business Development at Henry Schein, Inc., all the while having commercial responsibility within the pediatric and adult infectious disease vaccine market.

Russell Wilson

Mr. Russell P. Wilson is Senior Vice President - Business Development of Novavax, Inc., since November 2011. Mr. Wilson was most recently the Chief Financial Officer at Supernus Pharmaceuticals beginning in 2009. He was previously Senior Vice President, Chief Financial Officer and General Counsel of Iomai Corporation, which was acquired in 2008 by Intercell AG. He was the Acting General Counsel of North American Vaccine, Inc. until its acquisition by Baxter International in 2000.

Louis Fries

Dr. Louis F. Fries is Vice President and Chief Medical Officer of Novavax Inc. Dr. Fries had formerly served as Director of Clinical Development for GSK biologicals following the acquisition of ID Biomedical by GSK in 2005, and previously had been Vice President of Clinical and Regulatory Affairs at ID Biomedical. Dr. Fries received his medical degree from Duke University, has nearly 25 years of experience in the clinical testing and development of human vaccines, and has authored over 60 peer-reviewed publications. He has a BA degree from John Hopkins University.

D. Nigel Thomas

Dr. D. Nigel Thomas is Vice President of Clinical Operations at Novavax Inc. He had been Clinical Operations Director at Iomai beginning in 2006 and through its acquisition by Intercell. He has previously held a variety of clinical operation positions in the Biotechnology and CRO industry. Dr. Thomas received his Ph.D. in Biochemistry & Physiology from the University of Reading in the United Kingdom and has overseen numerous vaccine, drug and medical device clinical trials including global Phase 2 and Phase 3 clinical trials for vaccines.

Rajiv Modi

Dr. Rajiv I. Modi is Director of Novavax, Inc., since April 1, 2009. He is Managing Director of Cadila Pharmaceuticals, Ltd. (“Cadila”), a company organized in India, since 1995 and Director of other Cadila Group Companies. Dr. Modi was elected to the Board based upon his relationship with the Company’s largest stockholder at the time. As of April 16, 2013, Satellite Overseas (Holdings) Limited, a subsidiary of Cadila, holds approximately 8.3% of the Company’s outstanding Common Stock and, for so long as it holds at least 5% of the outstanding Common Stock, the Board will nominate for election as a director one representative of Cadila. Dr. Modi has extensive leadership experience, as well as technical expertise in the development and manufacturing of pharmaceutical products. He also brings broad experience in international joint ventures and pharmaceutical sales.

Richard Douglas

Dr. Richard H. Douglas is an Independent Director of Novavax, Inc., since 2010. He is Former Senior Vice President Corporate Development and a Corporate Officer of Genzyme Corporation. From 1989 to 2011 he led Genzyme's Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989, Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow in Leroy Hood's laboratory at the California Institute of Technology. He received a Ph.D. from the University of California, Berkeley in biochemistry and a B.S. in chemistry from the University of Michigan. He currently serves on the University of Michigan Technology Transfer National Advisory Board.

Gary Evans

Mr. Gary C. Evans is an Independent Director of Novavax, Inc. He is Chairman of the Board and Chief Executive Officer of Magnum Hunter Resources Corporation, a NYSE Amex listed oil and gas company since May 2009 and Chairman, President, Chief Executive Officer and Founder of GreenHunter Energy, Inc., a NYSE Amex listed alternative energy company, since 2007. Former Lead Independent Director of Novavax from March 2007 until April 2011 and Chairman of the Board of Directors of Novavax from April 2005 until March 2007. Mr. Evans was Chairman, President and Chief Executive Officer of Magnum Hunter Resources, Inc., a NYSE listed oil and gas exploration and production company, from 1995 to 2005 and Chairman and Chief Executive Officer of its predecessor, Hunter Resources, Inc., from 1985 to 1995. Mr. Evans is currently an Individual Trustee of TEL Offshore Trust, a publicly listed oil and gas trust and serves on the Board of the Maguire Energy Institute at Southern Methodist University. Mr. Evans is a serial entrepreneur, having founded, grown and provided successful exit strategies for several companies; in 2004 he was recognized by Ernst and Young as the Southwest Area 2004 Entrepreneur of the Year in the Energy Sector and was inducted into the World Hall of Fame for Ernst & Young Entrepreneurs.

John Marsh

Mr. John O. Marsh is an Independent Director of Novavax, Inc., since 1991. He is Distinguished Adjunct Professor of Law at George Mason University. Mr. Marsh was the Co-Chair of the Independent Review Group for Walter Reed Hospital and Bethesda Navy Medical Center. Mr. Marsh was a Visiting Professor of Ethics at Virginia Military Institute in 1998. He served as Interim Chief Executive Officer of Novavax from July 1996 to March 1997 and as Chairman of the Company’s Board of Directors from July 1996 to February 1997. He was Secretary of the Army from 1981 to 1989, a Counselor with Cabinet rank to the President of the United States from 1974 to 1977, Assistant for National Security Affairs to Vice President of the United States in 1974, and Assistant Secretary of Defense from 1973 to 1974. Mr. Marsh was a U.S. Representative in Congress from 1963 to 1971. He has been awarded the Department of Defense Distinguished Public Service Award on six occasions and was awarded the Presidential Citizens Medal from President Ronald Reagan. Mr. Marsh served on the executive committee of the Institute for Defense Analyses (IDA), a federal research institute, and continues to hold a consulting role with IDA. Mr. Marsh brings significant experience in government affairs and has a vast network of contacts in the U.S. government, including political appointees and elected officials. In addition, Mr. Marsh has a keen skill of recognizing leadership skills in management, areas for improvement, and developing those leadership skills within the Company’s management team.

Michael McManus

Mr. Michael A. McManus is an Independent Director of Novavax, Inc., since 1998.Mr. McManus served as President, Chief Executive Officer and Director of New York Bancorp Inc. from 1991 through March 1998. He also served as President and Chief Executive Officer of Home Federal Savings Bank, the principal subsidiary of New York Bancorp Inc., from February 1995 through March 1998. From 1990 through November 1991, Mr. McManus was President and Chief Executive Officer of Jamcor Pharmaceuticals Inc. Mr. McManus served as an Assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus received a BA in economics from the University of Notre Dame and a JD from the Georgetown University Law Center. Mr. McManus served in the U.S. Army Infantry from 1968 through 1970. He currently serves as a member of the Board of Directors of A. Schulman Inc. Mr. McManus is a recipient of the Ellis Island Medal of Honor. He has overseen the successful growth and development of businesses and products and, as chief executive officer of two public companies, has significant experience in governance, legal and risk management, and reading and understanding financial statements.

Basic Compensation

Search Stocks